Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Bertram Pitt

Cardiovascular Disease Ann Arbor, MI Medical Doctor

NPI 1316017742 CMS profile 13587

1500 East Medical Center Dr, 3Rd Floor Cardiovascular Center, Ann Arbor, MI 48109

Open in the dashboard

General payments

$297,759

126 records reported · program years 2019–2025

Research payments

$6,676

Paid to them · 14 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Bertram Pitt of Ann Arbor, MI is reported in the CMS Open Payments database as having received $297,759 across 126 general payments and $6,676 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of Cardiovascular Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

8 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $13,699 10
2025 Research $2,181 13
2023 General $39,537 2
2023 Research $4,495 1
2022 General $63,830 4
2021 General $15,955 11
2020 General $20,254 23
2019 General $144,484 76

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Bertram Pitt
  • Cardiovascular Disease median
  • Middle half of Cardiovascular Disease
  • National median

In program year 2025, general payments to Bertram Pitt were reported at $13,699. Among 16,617 Cardiovascular Disease profiles paid that year, the median was $432 and the middle half received between $132 and $1,252.

Show as a table
Year Bertram Pitt Cardiovascular Disease median Middle half National median
2019 $144,484 $450 $127–$1,392 $163
2020 $20,254 $242 $77–$751 $114
2021 $15,955 $335 $101–$1,037 $132
2022 $63,830 $395 $121–$1,211 $149
2023 $39,537 $443 $136–$1,283 $160
2024 $0 $450 $136–$1,323 $164
2025 $13,699 $432 $132–$1,252 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Vifor (International) Ltd. $102,872 10 payments
  2. Bayer HealthCare Pharmaceuticals Inc. $64,566 43 payments
  3. Sanofi US Services Inc. $47,729 3 payments
  4. Relypsa, Inc. $36,406 28 payments
  5. Boehringer Ingelheim Pharmaceuticals, Inc. $13,699 10 payments
  6. Boehringer Ingelheim International GmbH $10,500 3 payments
  7. AstraZeneca UK Limited $8,703 13 payments
  8. AstraZeneca AB $8,135 2 payments
  9. Eli Lilly and Company $3,000 1 payment
  10. Amgen Inc. $1,540 10 payments
  11. Other $608 3 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $201,057 54 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $49,065 2 payments
  3. Travel and Lodging $45,639 38 payments
  4. Food and Beverage $1,998 32 payments
Products named General payments · program years 2019–2025
  1. Veltassa Potassium Binder $50,445 5 payments
  2. SOTAGLIFLOZIN $47,729 3 payments
  3. Non-Covered $40,547 25 payments
  4. Veltassa Hyperkalemia $34,608 24 payments
  5. Non-Covered $11,984 10 payments
  6. JARDIANCE Diabetes $10,500 3 payments
  7. Kerendia $8,265 2 payments
  8. JARDIANCE Diabetes $3,000 1 payment
  9. ONGLYZA $1,500 3 payments
  10. LOKELMA $523 1 payment
  11. Other $20 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Bayer HealthCare Pharmaceuticals Inc. $4,495 1 payment
  2. Boehringer Ingelheim International GmbH $2,181 13 payments

Records

140 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Cardiovascular Disease in Michigan

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record